Astellas Pharma US, Inc. v. Department of Health and Human Services et al

  1. October 06, 2023

    Mapping Big Pharma's Blitz On Medicare Drug Price Talks

    Lawsuits from Big Pharma and big business challenging Medicare's new power to negotiate drug prices are hurtling toward pivotal tests of lofty legal theories and the Biden administration's creative efforts to save its signature health care accomplishment. Here, Law360 explores the litigation landscape in a detailed map that will be updated as the saga evolves.

  2. September 07, 2023

    Astellas Drops Suit Over Medicare Drug Price Negotiation Law

    Astellas Pharma on Wednesday dropped its challenge to the new Medicare drug price negotiation program after none of its products were selected for negotiation by the U.S. Department of Health and Human Services, taking a bit of heat off the agency as it faces a barrage of legal challenges to the landmark program.

  3. September 01, 2023

    Novartis Joins Legal Fray After Price Negotiation List Unveiled

    Novartis Pharmaceuticals Corp. on Friday joined the growing list of pharmaceutical companies challenging the Inflation Reduction Act, filing suit in New Jersey federal court just days after the Biden administration revealed the list of drugs in the inaugural round of Medicare price negotiations.

  4. August 14, 2023

    Drug Negotiation Suits Reflect Lobbying Failures, HHS Says

    A barrage of legal challenges to landmark legislation empowering Medicare to negotiate drug prices is little more than a failed lobbying campaign "masquerading as constitutional theory," the U.S. Department of Health and Human Services said in its first official rebuttal in the high-stakes litigation.

  5. July 21, 2023

    The Litigation Jolting Health & Life Sciences In 2023's 2nd Half

    A head-spinning spree of rulings and new lawsuits in 2023's first half is reverberating across the health care industry and auguring a dizzying denouement in the year's final months that may well upend assumptions about drug prices and approvals, the False Claims Act and the powers of federal regulators.

  6. July 17, 2023

    Astellas Says Drug Price Negotiation Law Is 'Unconstitutional'

    Drugmaker Astellas Pharma has added to growing allegations that the U.S. Department of Health and Human Services is illegally allowing Medicare to negotiate prescription drug prices under a federal inflation deterrent that went into effect last year, filing suit in Illinois federal court.